Group 1: Company Overview and Objectives - The main purpose of the acquisition of Hongjitang is to integrate high-quality traditional Chinese medicine assets within the group, creating a competitive healthcare platform [1] - The acquisition aims to enrich the company's product portfolio, enhancing its risk resistance and market competitiveness [1] - The company seeks to leverage synergies to improve operational efficiency and profitability [1] Group 2: Share Issuance and Pricing - The share issuance price for acquiring assets is set at 16.73 yuan per share, which complies with regulations stating that the price must not be lower than 80% of the market reference price [2] - The market reference price is based on the average trading price of the company's shares over the 20 trading days prior to the board resolution announcement [2] - The board has approved the issuance price, and related directors will abstain from voting in the upcoming shareholders' meeting [2]
科源制药(301281) - 301281科源制药投资者关系管理信息20250515